Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Healthtrust
Medtronic
QuintilesIMS
US Department of Justice
Deloitte

Generated: April 24, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Grn163l

« Back to Dashboard

US Patents for Grn163l

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Grn163l ➤ Sign Up Method for identification of sensitivity of a patient to telomerase inhibition therapy Geron Corporation (Menlo Park, CA) ➤ Sign Up
Grn163l ➤ Sign Up Combined telomerase inhibitor and gemcitabine for the treatment of cancer Geron Corporation (Menlo Park, CA) ➤ Sign Up
Grn163l ➤ Sign Up Cancer treatment by combined inhibition of proteasome and telomerase activities Geron Corporation (Menlo Park, CA) Memorial Sloan-Kettering Cancer Center (New York, NY) ➤ Sign Up
Grn163l ➤ Sign Up Compounds having anti-adhesive effects on cancer cells Geron Corporation (Menlo Park, CA) Board of Regents of the University of Texas System (Austin, TX) ➤ Sign Up
Grn163l ➤ Sign Up Method for identification of sensitivity of a patient to telomerase inhibition therapy Geron Corporation (Menlo Park, CA) ➤ Sign Up
Drugname Patent Number Patent Title Patent Assignee Estimated Expiration

Subscribe to access the full database, or try a Free Trial

International Patents for Grn163l

Drugname Country Document Number Estimated Expiration Related US Patent
Grn163l Cyprus 1117234 2028-10-17 ➤ Sign Up
Grn163l Cyprus 1119653 2028-10-17 ➤ Sign Up
Grn163l Denmark 2342360 2028-10-17 ➤ Sign Up
Grn163l Denmark 3029154 2028-10-17 ➤ Sign Up
Grn163l European Patent Office 2342360 2028-10-17 ➤ Sign Up
Drugname Country Document Number Estimated Expiration Related US Patent

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
UBS
Chinese Patent Office
Julphar
Citi
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.